SCHEMBL14676435

SCHEMBL14676435

CC(C)[Si](C#CC(C)(O)c1ccncc1)(C(C)C)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ CYP3A4 P08684 3/20 0.33
▸ KIF11 P52732 1/20 0.32
▸ CACNA2D1 P54289 1/20 0.32
▸ CACNB2 Q08289 1/20 0.32
▸ CACNA1C Q13936 1/20 0.32
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ NFKB1 P19838 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ HIF1A Q16665 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ ABCC9 O60706 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ GLA P06280 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14677129 0.78 CYP19A1 (0.39) CYP19A1CYP3A4
SCHEMBL17974815 0.76 CYP19A1 (0.39) USP2RAB9ACYP19A1CYP3A4KIF11
SCHEMBL1614526 0.70 CYP19A1 (0.41) USP2RAB9ACYP19A1CYP3A4KIF11
SCHEMBL15077772 0.68 CACNA2D1 (0.44) CYP3A4CACNA2D1CACNB2CACNA1CCYP1A2
SCHEMBL31252158 0.68 KDM4E (0.47) CYP3A4CACNA2D1CACNB2CACNA1CCYP1A2
SCHEMBL13741610 0.67 CYP19A1 (0.42) USP2RAB9ACYP19A1CYP3A4KIF11
SCHEMBL20710610 0.66 CYP19A1 (0.48) USP2RAB9ACYP19A1CYP3A4KIF11
SCHEMBL2554687 0.66 CYP19A1 (0.48) USP2RAB9ACYP19A1CYP3A4KIF11
SCHEMBL28197455 0.66 MEN1 (0.50) USP2RAB9ACYP19A1CYP3A4KIF11
SCHEMBL17963574 0.65 CYP3A4 (0.42) CYP19A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315881-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2014-10-23 — — US disclosed
US-20140315881-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2014-10-23 — — US disclosed
US-20140315881-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2014-10-23 — — US disclosed
EP-2736330-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2014-06-04 — — EP disclosed
WO-2013019682-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315881-A1 COMPOUNDS AND METHODS RORC, RORB, RORA USP2 3636/4885RAB9A 2352/4885CYP19A1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback